The intervention will benefit ~60,000 women and children in selected areas of Delhi
This initiative will prioritize nutrition outcomes by deepening partnership with the government to strengthen health and ICDS systems to promote evidence-based, sustainable, multi-sectoral actions for improved quality of health and nutrition
Takeda Biopharmaceuticals India Private Limited (formerly known as Baxalta Bioscience India Private Limited), a global values-based, R&D-driven biopharmaceutical leader conducted dissemination of its public health initiatives in strengthening the health system for rare diseases (RD) in India. These initiatives aim to improve access to healthcare
CINRYZE™ is plasma-derived C1-I NH approved for routine prevention (prophylaxis), short-term prevention or pre-procedure prevention, and acute attacks of HAE.
Among adult HAE patients, 51% miss at least one day of work (mean 3.3 days), 44% students miss at least one day of school